<DOC>
	<DOCNO>NCT00045500</DOCNO>
	<brief_summary>RATIONALE : UCN-01 may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining UCN-01 prednisone may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine UCN-01 prednisone treat patient refractory solid tumor lymphoma .</brief_summary>
	<brief_title>UCN-01 Prednisone Treating Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose UCN-01 combination prednisone patient refractory solid tumor lymphomas . - Determine toxic effect regimen patient . - Assess pharmacokinetics regimen patient . - Assess tumor response patient treat regimen . OUTLINE : This dose-escalation study UCN-01 . Patients receive oral prednisone daily day 1-5 UCN-01 IV 36-72 hour day 3-5 . Courses repeat every 28 day 2 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos UCN-01 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treat recommended phase II dose . Patients follow every 3-12 month 5 year . PROJECTED ACCRUAL : Approximately 24 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor lymphoma Progressive disease standard therapy No therapy likely improve survival Prostate cancer patient must progress hormonal therapy gonadotropinreleasing hormone ( GnRH ) agonists withdrawal testosterone receptor antagonists Patients must continue GnRH agonist study ( orchiectomy perform ) castrate testosterone level Brain metastasis allow treated patient stable antiseizure medication steroid &gt; 6 month No local complication disease require urgent therapy ( i.e. , hydronephrosis , spinal cord compression , severe pain require improve pain management ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count great 1,000/mm^3 Platelet count great 100,000/mm^3 12hour fasting glucose great 110 mg/dL OR 12hour fast glucose great 140 mg/dL hemoglobin A1C great 6.5 mg/dL Hepatic PT/PTT great 1.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN ( unless Gilbert 's syndrome present ) AST/ALT great 2.5 time ULN Renal Creatinine clearance great 60 mL/min OR Creatinine great 1.5 mg/dL Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris Pulmonary No interstitial lung disease within past year No requirement oxygen therapy hypoxia past 6 month Gastrointestinal No diagnosis duodenal gastric ulcer No severe gastritis within past 6 month Other HIV negative No prior allergic reaction indolocarbazoles No diabetes hyperglycemia within past year require diabetic diet , oral hypoglycemics , insulin No uncontrolled illness No active infection No seizure disorder No psychiatric illness would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior UCN01 Endocrine therapy See Disease Characteristics No concurrent oral IV steroid Radiotherapy At least 4 week since prior radiotherapy recover Surgery See Disease Characteristics At least 21 day since prior major surgery Other See Disease Characteristics At least 4 week since prior investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>